# Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

> **NCT01124149** · PHASE4 · COMPLETED · sponsor: **Shire** · enrollment: 759 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** MMX mesalamine/ mesalazine

## Key facts

- **NCT ID:** NCT01124149
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-29
- **Primary completion:** 2012-12-07
- **Final completion:** 2012-12-07
- **Target enrollment:** 759 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124149, "Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01124149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*